Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression
The proposed study is a single-site, randomized, controlled clinical trial (RCT)
comparing ketamine-assisted psychotherapy (KAP) to a standard evidence-based regimen of
ketamine administered in a medical model without psychotherapy (KET). Eligible study
participants ...
Age: 18 - 90 years
Gender: All
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)
The purpose of this study is to evaluate the long-term safety and tolerability of
BHV-7000, in participants with Major Depressive Disorder (MDD).
Age: 18 - 75 years
Gender: All
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
The purpose of this study is to determine the efficacy and safety of BHV-7000 in
participants with Major Depressive Disorder (MDD)
Age: 18 - 75 years
Gender: All
Neural Circuit Effects of Ketamine in Depression
This project is designed to examine the role of the subgenual anterior cingulate cortex (sgACC) in anhedonia and anxiety in humans with depression, as well as the acute and sustained effects of ketamine on agACC activation and depression symptoms.
Age: 18 - 65 years
Gender: All
Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment
Ketamine is a NMDA-receptor antagonist that promotes synapse formation and has been shown to
rapidly improve symptoms in depression. Even a single dose of ketamine has been shown to
improve depression and cognition with short-term memory, inhibitory control, cogniti...
Age: 50 - 90 years
Gender: All
Network Neurofeedback Using 7-Tesla MRI to Reduce Rumination Levels in Depression
Patients with major depressive disorder (MDD) exhibit increased levels of rumination (i.e.
repetitive thinking and focus on negative mood states) which have been found to increase the
risk of depressive relapse. The ability to reduce rumination levels among these pa...
Age: 18 - 65 years
Gender: All
DBS for TRD With the Medtronic Percept PC
Of the estimated 30 million Americans who suffer from Major Depressive Disorder, approximately 10% are considered treatment resistant. Deep brain stimulation (DBS) to a region of the brain called the subcallosal cingulate (SCC) is an emerging strategy for treatment resi...
Age: 25 - 70 years
Gender: All
A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
In this study, researchers will learn more about a study drug called BIIB122 in participants
with early-stage Parkinson's disease (PD). The study will focus on participants with a
specific genetic variant in their LRRK2 gene.
The main question researchers are tr...
Age: 30 - 80 years
Gender: All
Invasive Decoding and Stimulation of Altered Reward Computations in Depression
Novel invasive neurostimulation stimulation strategies through neurosurgical interventions
are emerging as a promising therapeutical strategy for major depressive disorder. These have
been applied mostly to the anterior cingulate cortex, but other limbic brain regio...
Age: 18 - 80 years
Gender: All
Pediatric GVHD Low Risk Steroid Taper Trial
The standard treatment for acute graft-vs-host disease (GVHD) is to suppress the activity of
the donor immune cells using steroid medications such as prednisone. Although most GVHD,
especially in children, responds well to treatment, sometimes (around 1/3 of the tim...
Age: Birth - 21 years
Gender: All
The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy
Ketamine is a medication that came into clinical practice in the 1960's. Ketamine is used as
an anesthetic and to provide pain relief. Recently, Ketamine was approved to treat drug
resistant depression using subanesthetic doses. In the hospital setting, intravenous
...
Age: 18 years - 66+
Gender: All
Targeting IL-17A for Treatment-Resistant Depression
The proposed study aims to test ixekizumab, a monoclonal antibody (mAb) against interleukin
17A (IL-17A), in patients with treatment-resistant depression (TRD).
Age: 18 - 65 years
Gender: All
XEN1101 for Major Depressive Disorder
This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype
as a novel treatment target for mood disorders through the administration of the
KCNQ-selective channel opener XEN1101 (Xenon Pharmaceuticals).
Age: 18 - 65 years
Gender: All
The Long-term Impact of a Light Intervention on Sleep and Cognition in Mild Cognitive Impairment
To investigate the impact of a long-term light treatment intervention on sleep physiology and
memory in mild cognitively impaired and mild Alzheimer's disease patients living at home. The
goal is also to measure the impact of the lighting intervention on caregivers'...
Age: 50 years - 66+
Gender: All
The Long-term Impact of a Light Intervention on Sleep and Cognition in Mild Cognitive Impairment
To investigate the impact of a long-term light treatment intervention on sleep physiology
and memory in mild cognitively impaired and mild Alzheimer's disease patients living at
home. The goal is also to measure the impact of the lighting intervention on caregivers'
...
Age: 50 years - 66+
Gender: All
Neuraxial Preservative Free Morphine for Normal Spontaneous Vaginal Delivery
Patients presenting for normal spontaneous vaginal delivery who have a neuraxial anesthestic
will be randomized to receive preservative free morphine or saline placebo after delivery.
Age: 18 years - 66+
Gender: Female
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Objectives of this study are to determine whether active VNS Therapy treatment is superior to
a no stimulation control in producing a reduction in baseline depressive symptom severity,
based on multiple depression scale assessment tools at 12 months from randomizati...
Age: 18 years - 66+
Gender: All
Telemedicine in Age-Related Macular Degeneration (AMD)
AMD affects 15 million Americans, with 200,000 new advanced cases diagnosed each year. AMD is the leading cause of blindness in this country, from either the “dry” or “wet” advanced forms. At present, there is no treatment for dry AMD. Besides bl...
Age: 50 - 90 years
Gender: All
Light and the Effect on Metabolic Syndrome and Alzheimer's Disease
This study's main hypothesis is that a delivering a tailored lighting intervention (TLI) will
provide a successful means for promoting circadian entrainment and treating metabolic disease
and inflammation in patients with mild cognitive impairment (MCI) and Alzheime...
Age: 55 years - 66+
Gender: All
ToRsemide compArisoN with furoSemide FOR Management of Heart Failure (TRANSFORM-HF)
An approximately 6000-patient, randomized, unblinded, two-arm, multicenter clinical trial comparing torsemide with furosemide among patients hospitalized for heart failure. 1:1 randomization to either oral torsemide OR oral furosemide (dosing at discretion of local pr...
Age: 18 - 85 years
Gender: All